{"record_key":"ocugenix-corp","identifier":"ocugenix-corp","external_key":"6DB20F","title":"Ocugenix Corp.","summary":null,"url":"https://inventions.pitt.edu/startups/ocugenix-corp","json_url":"https://inventions.pitt.edu/startups/ocugenix-corp.json","object_key":"startups","description":"Ocugenix is developing treatments for eye diseases involving abnormal blood-vessel growth, inflammation and fibrosis. Built on University of Pittsburgh wound-healing research, its approach activates CXCR3 signaling to address these connected processes. Programs include wet age-related macular degeneration, geographic atrophy, proliferative diabetic retinopathy and dry eye disease. [1]: https://ocugenix.com/\nFounded by Sean McDonald, Alan Wells, Cecelia Yates and Ian Conner, Ocugenix has advanced its investigational programs through early clinical studies, including Phase IIa work, while preparing its dry-eye program for clinical development. [2]: https://ocugenix.com/ [3]: https://ocugenix.com/team/ [4]: https://www.innovation.pitt.edu/pitt-startup-check-in-ocugenix/","attributes":[{"key":"website","label":"Website","values":["https://ocugenix.com/"]},{"key":"sector","label":"Sector","values":["Therapeutics"]},{"key":"therapeutic_areas","label":"Therapeutic Areas","values":["Ophthalmology"]},{"key":"therapeutic_indications","label":"Therapeutic Indications","values":["Diabetic retinopathy","Dry eye syndrome"]},{"key":"funding_stage","label":"Funding Stage","values":["Seed"]},{"key":"founders","label":"Founders","values":["Sean McDonald","Cecelia Yates","Alan Wells","Ian Conner"]}],"related":[]}